A clinical retrospective study of teniposide intra-arterial chemotherapy combined with bevacizumab in treatment of recurrent high-grade glioma
Objective:To investigate the efficacy and safety of teniposide superselective intra-arterial chemotherapy combined with be-vacizumab in the treatment of recurrent high-grade glioma.Methods:According to the treatment method,79 patients with recurrent high-grade glioma were divided into experimental group with 37 patients(teniposide intra-arterial chemotherapy combined with beva-cizumab)and control group with 42 patients(bevacizumab monotherapy).The two groups were compared in terms of objective re-sponse rate,disease control rate,and the incidence rate of adverse reactions,and the impact of the gene promoter methylation status of O6-methylguanine-DNA methytransferase on disease control rate was analyzed.Results:The objective response rate was 43.2％in the experimental group and 21.4％in the control group(P=0.038),and the disease control rate was 78.4％in the experimental group and 54.8％in the control group(P=0.027).Compared with the control group,the experimental group had significantly higher incidence rates of the adverse reactions such as mild gastrointestinal reactions(P=0.044),headache(P=0.044),and leucopenia(P=0.026).Com-pared with the control group,the experimental group had a significantly higher disease control rate in the population aged＜60 years(P＜0.05).Conclusion:Teniposide superselective intra-arterial chemotherapy combined with bevacizumab has better efficacy than bevaci-zumab monotherapy in the treatment of recurrent high-grade glioma and thus holds promise for further clinical application.
万方数据
维普
